Melanoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Melanoma Market Outlook
Thelansis’s “Melanoma Market Outlook,
Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034"
covers disease overview, epidemiology, drug utilization, prescription share
analysis, competitive landscape, clinical practice, regulatory landscape,
patient share, market uptake, market forecast, and key market insights under
the potential Melanoma treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Melanoma
Overview
Melanoma
originates from melanocytes found in pigmented tissues, including the skin,
eyes, and intestines. Approximately 90% of melanoma cases are initially
diagnosed as primary tumors, showing no signs of metastasis. However, melanoma
tends to spread to the brain when it becomes malignant. The major oncogenic
mutations associated with melanoma involve genes like BRAF, NRAS, c-KIT, PTEN,
and GNAQ/GNA11. Among these, BRAF mutations are the most extensively studied,
with a prevalence ranging from 50% to 60% in primary melanoma cases. A small
percentage, around 5% to 12% of melanoma patients, have a family history of
cutaneous malignant melanoma (CMM) in their first-degree relatives. Over 75
somatic mutations in the BRAF gene have been identified in melanoma, all of
which lead to the constitutive activation of BRAF. These mutations are found in
the activating segment within exon 15 or the glycine-rich loop (P-loop) in exon
11 of the BRAF protein’s kinase domain. In BRAF mutant melanoma cases, V600E
mutations account for 74% to 90%, while V600K mutations make up 16% to 29% of
the cases. The frequency of BRAF mutations in primary melanomas varies from 50%
to 60%.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment